This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Lazertinib
DrugBank Accession Number
DB16216
Background

Lazertinib is under investigation in clinical trial NCT04487080 (A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-small Cell Lung Cancer).

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 554.655
Monoisotopic: 554.275386987
Chemical Formula
C30H34N8O3
Synonyms
  • Lazertinib
External IDs
  • GNS-1480
  • GNS1480
  • YH-25448
  • YH25448

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
4A2Y23XK11
CAS number
1903008-80-9
InChI Key
RRMJMHOQSALEJJ-UHFFFAOYSA-N
InChI
InChI=1S/C30H34N8O3/c1-5-28(39)32-23-17-24(26(40-4)18-25(23)37-13-15-41-16-14-37)33-30-31-12-11-27(34-30)38-20-22(19-36(2)3)29(35-38)21-9-7-6-8-10-21/h5-12,17-18,20H,1,13-16,19H2,2-4H3,(H,32,39)(H,31,33,34)
IUPAC Name
N-{5-[(4-{4-[(dimethylamino)methyl]-3-phenyl-1H-pyrazol-1-yl}pyrimidin-2-yl)amino]-4-methoxy-2-(morpholin-4-yl)phenyl}prop-2-enamide
SMILES
COC1=C(NC2=NC=CC(=N2)N2C=C(CN(C)C)C(=N2)C2=CC=CC=C2)C=C(NC(=O)C=C)C(=C1)N1CCOCC1

References

General References
Not Available
ChemSpider
64835231

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
3RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)2
2Not Yet RecruitingTreatmentEGF-R Positive Non-Small Cell Lung Cancer / Locally Advanced Non-Small Cell Lung Cancer / Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)1
2Not Yet RecruitingTreatmentMetastatic Non-small Cell Lung Cancers1
2Not Yet RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)2
2RecruitingTreatmentMetastatic Non-Small Cell Lung Cancer / Non-small Cell Lung Cancer (NSCLC), Recurrent1
2RecruitingTreatmentNeoplasms, Lung1
1CompletedBasic ScienceHealthy Subjects (HS)1
1CompletedOtherHealthy Subjects (HS)1
1CompletedTreatmentHealthy Adult Volunteers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.025 mg/mLALOGPS
logP4.05ALOGPS
logP4.55ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)13.65ChemAxon
pKa (Strongest Basic)8.35ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area109.67 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity162.61 m3·mol-1ChemAxon
Polarizability59.53 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at December 15, 2020 18:15 / Updated at February 21, 2021 18:55